This content was accurate at the time of release, 1 November 2021. Accreditation for this course expired on 2 November 2022. If you would still like an activity completion certificate, send your request to firstname.lastname@example.org.
This online learning module is designed to raise awareness for HCM and provide you with an understanding of how heart failure symptoms should be managed in HCM disease. It assists clinicians in community practice or those with an interest in HCM management to:
- understand the heart failure symptoms in HCM
- correctly manage the heart failure symptoms within each hemodynamic category of HCM
- provide appropriate management of atrial fibrillation
- know when referral to an HCM expert center is appropriate
This online learning module is designed to be completed in 60 minutes.
Target audience: Family/general physicians, general/community cardiologists, cardiac nurses, paediatricians, paediatric nurses, genetic counselors
Funding disclosure: This activity is supported by educational grant funding from Bristol Myers Squibb, Cytokinetics and Sanofi.
Learners may participate in this educational activity free of charge.
- Heart failure symptoms in HCM: background
- Treatment of heart failure symptoms in obstructive and nonobstructive HCM
- Future therapies
- Atrial fibrillation
By the end of this activity, learners will be able to:
- Outline steps to take to mitigate heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) and apply these to an example patient
- Contrast the strengths and limitations of medical and invasive therapies for heart failure symptoms in patients with obstructive HCM and apply appropriately to sample patient data
- Summarize contemporary management strategies for heart failure symptoms in patients with nonobstructive HCM
- Recognize the signs of the advanced heart failure stage of HCM and employ appropriate management strategies for sample patients
- List strategies for treatment of atrial fibrillation in patients with HCM and utilize these on an example patient
Accreditation for this course has expired. You may view the program, but CME / CE is no longer available and no certificate will be issued.
Dr Martin Maron, MD, Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, has received financial compensation for consulting for Cytokinetics and Imbria, and received research grants from Takeda and iRhythm.
Dr Anjali Tiku Owens, MD, Medical Director of the Advanced Heart Failure and Transplant Cardiology, Penn Center for Inherited Cardiovascular Disease/ University of Pennsylvania, received financial compensation for consulting for MyoKardia/BMS and Cytokinetics.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.